longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ì	pe Response													
1. Name and Address of Reporting Person * Hui Liu				2. Issuer Name and Ticker or Trading Symbol Matings Rio Pharma Holdings Inc. [MTNR]					5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				Matinas BioPharma Holdings, Inc. [MTNB] 3. Date of Earliest Transaction (Month/Day/Year) 01/01/2021										
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person				
BEDMINSTER,, NJ 07921										Form filed by More than One Reporting Person				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu					es Acquire	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			Execution Date, if any (In: (Month/Day/Year)			(Instr. 3, 4 and 5) (A) or		of (D) Ov Tra	Transaction(s) (Instr. 3 and 4)			Ownership Form: Direct (D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder:	Report on a	separate line for each		- Deriva	tive Securitie	es Acc	Persons in this f a currer	s who respon orm are not ro tly valid OME sed of, or Bene	equired to 3 control ficially Ov	respond ι number.				1474 (9-02)
1. Title of	2.	3. Transaction	3A. Deemed	(e.g., pt	5. Numb		6. Date Exe	vertible securi	7. Title an	d Amount	8. Price of	9. Number of	10.	11. Natur
Derivative Security (Instr. 3)	Conversion		Execution Date, if	Transaction Derivative Securities		ve s l (A) sed of	Expiration Date (Month/Day/Year) A) d of		Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owners Form of Derivati Security Direct (I or Indirects)	nip of Indirect Beneficia Ownershi (Instr. 4)
				Code	V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Stock option (right to buy)	\$ 1.36	01/01/2021		A	250,00	0	(1)	12/31/2030	Commo Stock	n 250,000	\$ 0	250,000	D	
Repoi	rting O	wners												
						R	elationships							
Reporting Owner Name / Address			Director 10% Owner		Of	Officer		Other						
Hui Liu C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER,, NJ 07921						C	Chief Techn	ology Office	r					
Signa	turos													

/s/ Keith A. Kucinski, attorney-in fact for Hui Liu		01/04/2021		
Signature of Reporting Person		Date		
	ı			

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with (1) the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.